Healthy volunteers to test two batches of new diabetes drug
NCT ID NCT07670897
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial will check whether two different ways of making the experimental drug GZR4 produce the same levels in the blood. About 64 healthy men will receive a single shot of one version or the other. The study is not designed to treat diabetes, but to ensure future batches are consistent.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GZR4 injection
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T2D are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gan & Lee Pharmaceuticals Shandong Co., Ltd.,
Linyi, Shandong, 276000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hidden liver risk in diabetes patients revealed
- Spud-tacular study: potatoes may ward off diabetes in seniors
- Can a fitbit and AI texts get sedentary diabetes patients moving?
- New diabetes drug shows promise for teens in landmark trial
- Could a diabetes drug protect kidneys in obesity? new trial investigates